Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.

被引：0
|
作者：
Patel, Sapna Pradyuman
Forget, Marie-Andree
Kreidieh, Firas Y.
Pelster, Meredith
Davies, Michael A.
Amaria, Rodabe Navroze
Gombos, Dan S.
Bernatchez, Chantale
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cell Therapy Mfg Ctr, Houston, TX USA
[3] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[4] MD Anderson Canc Ctr & Resilience, Cell Therapy Mfg Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9513
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Long survival associated with receipt of anti-CTLA-4 in patients with metastatic melanoma from acral lentiginous, mucosal and uveal primary tumors
    Klemen, Nicholas
    Wang, Melinda
    Olino, Kelly
    Clune, James
    Ariyan, Stephan
    Cha, Charles
    Weiss, Sarah
    Kluger, Harriet
    Sznol, Mario
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [42] Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086
    Loi, S.
    Adams, S.
    Schmid, P.
    Cortes, J.
    Cescon, D. W.
    Winer, E. P.
    Toppmeyer, D. L.
    Rugo, H. S.
    De laurentiis, M.
    Nanda, R.
    Iwata, H.
    Awada, A.
    Tan, A.
    Wang, A.
    Aktan, G.
    Karantza, V.
    Salgado, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Impact of Clinical and Pathologic Features on Tumor-Infiltrating Lymphocyte Expansion from Surgically Excised Melanoma Metastases for Adoptive T-cell Therapy
    Joseph, Richard W.
    Peddareddigari, Vijay R.
    Liu, Ping
    Miller, Priscilla W.
    Overwijk, Willem W.
    Bekele, Nebiyou B.
    Ross, Merrick I.
    Lee, Jeffrey E.
    Gershenwald, Jeffrey E.
    Lucci, Anthony
    Prieto, Victor G.
    McMannis, John D.
    Papadopoulos, Nicholas
    Kim, Kevin
    Homsi, Jade
    Bedikian, Agop
    Hwu, Wen-Jen
    Hwu, Patrick
    Radvanyi, Laszlo G.
    CLINICAL CANCER RESEARCH, 2011, 17 (14) : 4882 - 4891
  • [44] OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma
    Amaria, Rodabe Navroze
    McQuade, Jennifer Leigh
    Davies, Michael A.
    Glitza, Isabella Claudia
    Jose, Steffy
    Cressman, Erik Norman Kraske
    Clausell, Ashlynd L.
    Bassett, Roland L., Jr.
    Patel, Sapna Pradyuman
    Diab, Adi
    Tawbi, Hussein A.
    Wong, Michael K. K.
    Ikeguchi, Alexandra
    Haymaker, Cara L.
    Lee, Seoung-Ae
    Jagasia, Madan H.
    Ramsingh, Giridharan
    Prabhakar, Prakash
    Duan, Raina
    Hari, Parameswaran N.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Development of a Superior Method for the Reliable Expansion of Tumor-Infiltrating Natural Killer cells from Rare Human Malignancies for the Purposes of ex vivo Immunophenotyping and Immunotherapy
    Badeti, Saiaditya
    Minh Ma
    Deb, Pratik
    Alhatem, Albert
    Algarrahi, Khalid
    Agarwalla, Pankaj
    Liu, Dongfang
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1063 - 1064
  • [46] Development of a Superior Method for the Reliable Expansion of Tumor-Infiltrating Natural Killer cells from Rare Human Malignancies for the Purposes of ex vivo Immunophenotyping and Immunotherapy
    Badeti, Saiaditya
    Minh Ma
    Deb, Pratik
    Alhatem, Albert
    Algarrahi, Khalid
    Agarwalla, Pankaj
    Liu, Dongfang
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1063 - 1064
  • [47] An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
    Galvao, V.
    Palomero, J.
    Creus-Gonzalez, I.
    Lostes Bardaji, M. J.
    Lozano-Rabella, M.
    Garcia-Garijo, A.
    Yuste, A.
    Rodriguez, L.
    Villalobos Alberu, X.
    Rotxes, M.
    Vieito Villar, M.
    Santa Gadea, O. Saavedra
    Alonso, G.
    Brana, I.
    Munoz-Couselo, E.
    Querol, S.
    Tabernero, J.
    Martin-Lluesma, S.
    Gros, A.
    Garralda, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S650 - S650
  • [48] Trial in progress: A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma
    Thomas, Sajeve S.
    Chesney, Jason A.
    Hamid, Omid
    In, Gino K.
    Shoushtari, Alexander N.
    Samhouri, Yazan
    Hari, Parameswaran
    Ramsingh, Giridharan
    Prabhakar, Prakash
    Mclaughlin, Lauren
    Warner, Allison Betof
    CANCER RESEARCH, 2024, 84 (07)
  • [49] FUNCTIONAL AND PHENOTYPIC ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES ISOLATED FROM HUMAN PRIMARY AND METASTATIC LIVER-TUMORS AND CULTURED IN RECOMBINANT INTERLEUKIN-2
    TAKAGI, S
    CHEN, K
    SCHWARZ, R
    IWATSUKI, S
    HERBERMAN, RB
    WHITESIDE, TL
    CANCER, 1989, 63 (01) : 102 - 111
  • [50] OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy induced deepening and durable responses without interleukin 2 (IL2) in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma
    Amaria, Rodabe N.
    McQuade, Jennifer L.
    Davies, Michael A.
    Oliva, Isabella C. Glitza
    Jose, Steffy
    Cressman, Erik N.
    Clausell, Ashlynd L.
    Bassett, Roland
    Patel, Sapna
    Diab, Adi
    Tawbi, Hussein A.
    Wong, Michael K.
    Ikeguchi, Alexandra P.
    Jagasia, Madan
    Ramsingh, Giridharan
    Prabhakar, Prakash
    Duan, Raina
    Hari, Parameswaran
    CANCER RESEARCH, 2024, 84 (07)
12345